Related Experiment Videos
Comparative embryonic cytotoxicity of antiretroviral nucleosides
P Toltzis1, T Mourton, T Magnuson
1Department of Pediatrics, Case Western Reserve University, School of Medicine, Cleveland, Ohio.
Abstract:
Previous experiments have indicated that zidovudine is cytotoxic to early murine embryos both in vivo and in vitro. Newer nucleoside analogs (ddI, ddC, and d4T) with antiretroviral activity were tested to determine whether they had similar toxicity. Exposure of two-cell embryos to each of these three drugs inhibited blastocyst formation only at concentrations > or = to 100 microM. Sublethal preblastocyst exposure to d4T resulted in failure to develop beyond the blastocyst stage at 10 microM; no effect was seen with ddC or ddI at concentrations up to 100 microM. In each instance, however, cytotoxicity of all three drugs was significantly less than with zidovudine at equivalent concentration. These experiments suggest that newer antiretroviral nucleosides may be safer to use in early pregnancy than zidovudine.
Insights
Newer antiretroviral nucleosides like ddI, ddC, and d4T show less toxicity to early murine embryos than zidovudine. These findings suggest newer drugs may be safer for use during early pregnancy.
Area of Science:
- Reproductive toxicology
- Pharmacology
- Developmental biology
Background:
- Zidovudine (AZT) demonstrates cytotoxicity to early murine embryos.
- Antiretroviral nucleoside analogs are critical in managing HIV/AIDS.
- Assessing the embryonic toxicity of newer analogs is crucial for patient safety.
Purpose of the Study:
- To evaluate the in vitro cytotoxicity of newer antiretroviral nucleoside analogs (ddI, ddC, d4T) on early murine embryos.
- To compare the embryonic toxicity of these newer drugs with zidovudine.
Main Methods:
- Murine two-cell embryos were exposed to varying concentrations of ddI, ddC, and d4T.
- Embryo development was assessed by monitoring blastocyst formation and post-blastocyst development.
- Cytotoxicity was quantified and compared across different drug concentrations and with zidovudine.
Main Results:
- ddI, ddC, and d4T inhibited blastocyst formation at concentrations >= 100 microM.
- d4T showed developmental toxicity at 10 microM, while ddI and ddC did not up to 100 microM.
- All tested nucleoside analogs exhibited significantly lower cytotoxicity than zidovudine at equivalent concentrations.
Conclusions:
- Newer antiretroviral nucleoside analogs (ddI, ddC, d4T) display reduced embryonic cytotoxicity compared to zidovudine.
- These findings suggest a potentially improved safety profile for newer antiretroviral drugs in early pregnancy.
- Further research is warranted to confirm these findings in clinical settings.